Increased CD39 Nucleotidase Activity on Microparticles from Patients with Idiopathic Pulmonary Arterial Hypertension
Figure 7
Microparticle ADPase inhibition using anti-CD39 monoclonal antibody.
(A) TLC performed following anti-CD39 pre-treatment of microparticles from healthy controls and IPAH patients (Cont+ab and IPAH+ab) shows a decrease in the dephosphorylation of 14C ADP to AMP and adenosine (ADO) in both groups compared to samples without antibody pre-treatment (Cont and IPAH). The ADP lane contains 14C ADP subjected to the same experimental conditions but without microparticles. Quantification of the percent of available 14C ADP converted to AMP and ADO (B) reveals a relative decrease in nucleotidase activity of 62% in controls and 63% in IPAH patients (normalized to samples not pre-treated with antibody).